Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Tango Therapeutics's TNG-908?
TNG-908 is a small molecule commercialized by Tango Therapeutics, with a leading Phase II program in Soft Tissue Sarcoma. According...
Data Insights
Risk adjusted net present value: What is the current valuation of Tango Therapeutics's TNG-908?
TNG-908 is a small molecule commercialized by Tango Therapeutics, with a leading Phase II program in Squamous Non-Small Cell Lung...